Comparative Pharmacology
Head-to-head clinical analysis: BONIVA versus EXDENSUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BONIVA versus EXDENSUR.
BONIVA vs EXDENSUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
EXDENSUR (generic name not specified) is a novel oral anticoagulant that selectively inhibits activated factor XI (FXIa), thereby reducing thrombin generation and preventing clot formation without significantly affecting hemostasis.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
5 mg orally twice daily
None Documented
None Documented
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Terminal elimination half-life is 8 hours in healthy adults, prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Primarily renal excretion of unchanged drug (85%) and minor biliary excretion (15%). Total clearance is 120 mL/min.
Category C
Category C
Bisphosphonate
Bisphosphonate